Amyloid clearance is hit from several separate directions on my panel, which is why the response stacks more than one lever instead of picking a favorite.
The genotype is the pair I actually carry. Prevalence is printed only when the report printed it.
Decreased levels of the protein that processes amyloid-beta, so more can accumulate.
The clearance side of the story starts thin. That is why this spoke does not treat amyloid as a single-gene problem.
Reduced ability to break down amyloid-beta peptide in the brain.
Coffee and intermittent fasting show up later because of this row — and they collide with the caffeine story on the mood spoke.
Mitochondrial outer-membrane pores more prone to clogging with amyloid; long-run mitochondrial damage.
This is the third independent angle, not a repeat of ABCA7. APOC1 sits next to it as a caveat, not as a free-standing risk.
Leukoaraiosis and hippocampal atrophy are the printed associations.
I am not turning that into a scan claim. Imaging does not measure this mechanism directly.
The report calls BDNF “essentially fertilizer for the neurons.” Lower BDNF means more difficulty stimulating brain growth.
Named levers, straight from the report: moderate-to-intense aerobic exercise, butyrate, curcumin, and prebiotic high-fiber foods. This is the most actionable optimistic finding on the cluster.
APOC1 came back RI, high impact, odds ratio 2.79. The report is explicit: there is no risk identified for people who have this variant but do not have an APOE e4 variant. I am not going to let that 2.79 stand unqualified.
Those levers are tied to the clearance rows on this spoke. Coffee remains in tension with the caffeine flags on the mood spoke. I am leaving that fight unresolved.
How it works is the primer. The library is the index. The other spokes are the payload.
BDNF is the bright line. The rest of the workup still lives on the two instrument pages.